Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioton SA

www.bioton.pl

Latest From Bioton SA

Sinopharm/Oramed Deal Sets Up Huge China Market For Oral Insulin

Chinese pharmaceutical giant Sinopharm’s subsidiary has finalized a licensing agreement with Israeli firm Oramed for China rights to an oral insulin capsule, paving the way for further changes in the country’s huge diabetes market. Hefei meanwhile is pushing ahead with plans to become China’s high-end insulin production base, helped by several cross-border collaborations.

BioPharmaceutical China

Genovate Aims For Global Insulin Position Under $1bn Project

Genovate has begun construction of its first manufacturing facility for insulins as part of a total investment of $1bn and with the ambition to become China’s first, and the world's fourth largest, manufacturer of insulin using efficient and ecologically friendly production technology.

BioPharmaceutical China

Europe Backs Celgene’s Pomalidomide And Aegerion’s Lomitapide

Positive opinions from Europe's top drug assessment panel in May have included a long-acting "biobetter" lipegfilgrastim from Teva, a once-weekly HGH injection from Biopartners GmbH, and a smallpox vaccine developed by Bavarian Nordic with funding from the U.S. BioShield program.

BioPharmaceutical Europe

Mylan inks deal with Biocon for insulin analogs but preps for more in India?

Mylan, the world's third largest generics and specialty pharmaceutical company, is upping its engagement with Indian firms. It has entered into a collaboration with Biocon, India's largest biotechnology company by revenue, to develop and commercialize generic versions of three insulin analog products, amid talk that it may also be keen to snap up a formulations plant.

Poland
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Eastern Europe
        • Poland
  • Parent & Subsidiaries
  • Bioton SA
  • Senior Management
  • Slawomir Ziegert, CEO
  • Contact Info
  • Bioton SA
    Phone: (48) 22 721 40 00
    Macierzysz, ul. Poznanska 12
    Ozarów Mazowiecki, 05-850
    Poland
UsernamePublicRestriction

Register